Sentences with phrase «by ipilimumab»

They are investigating bacteria that could influence other immune therapies, such at the CTLA - 4 pathway, exploited by ipilimumab.

They are investigating other bacteria that could influence other immune therapies, such at the CTLA - 4 pathway, exploited by ipilimumab.

Not exact matches

«Ipilimumab works by stimulating the immune system against tumour antigens.

Indeed, the authors point out that Ipilimumab might better effect recurrence - free survival than adjuvant interferon and should be considered as an option by oncologists in this field considering its activity across subgroups including those with high tumor burden.

As reported in 2015, the study met its primary endpoint after a median follow up of 2.3 years, with ipilimumab significantly improving recurrence - free survival.2 The drug was subsequently approved by the US Food and Drug Administration as adjuvant therapy for stage III melanoma.

By blocking CTLA - 4, ipilimumab releases the brake, allowing cell - killing T cells to assault the cancer cells.

Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer — a median 17.5 months vs. 12.7 months — if they simultaneously received an immune stimulant, according to a study led by Dana - Farber Cancer Institute scientists.

Ipilimumab works by releasing the brakes on T - cells so they can attack tumors.

To confirm that possibility, the researchers transferred the microbes into mice that had no intestinal bacteria, either by feeding the microorganisms to the animals or giving them the Bacteroides - rich feces of some ipilimumab - treated patients.

In this group of patients, 72 received ipilimumab plus nivolumab, followed by nivolumab alone, while 37 got ipilimumab plus placebo.

Ipilimumab interferes with a process by which the immune system controls the activation of T cells that destroy diseased tissues.

The first of these drugs, ipilimumab (Yervoy ®) was approved by federal regulators to treat advanced melanoma.

By targeting CTLA - 4, ipilimumab restimulates the immune system to target tumor cells.

Drugs such as ipilimumab, which is given to people with advanced melanoma, work by activating the immune system to help it fight cancer.

The drugs, ipilimumab (Yervoy ®) and nivolumab (Opdivo ®), made by Bristol - Myers Squibb (BMS), are two immune checkpoint inhibitors that «release the brakes» on the immune system, allowing it to mount a stronger and more effective attack against cancer.

A University of California at Los Angeles (UCLA) study headed by Antoni Ribas, M.D., Ph.D., is a first - in - human phase I clinical trial combining adoptive cell transfer of a T cell receptor engineered to recognize NY - ESO - 1 along with Yervoy ® (ipilimumab, anti-CTLA-4).

By week 67, only 16 patients completed PRO assessments in each arm; attrition was highest in the ipilimumab arm, he noted.

In 2011, ipilimumab (Yervoy)-- which targets the CTLA - 4 pathway — was approved by the FDA to treat unresectable or metastatic melanoma.

Ipilimumab was tested in late - phase clinical trials by Jedd D. Wolchok, M.D., Ph.D., director of the CRI / Ludwig clinical trials network and associate director of CRI's Scientific Advisory Council.

The immune - based treatment Yervoy (ipilimumab) was the first drug shown to extend survival among patients with advanced melanoma and was approved by the FDA in 2011.

This may be best addressed by a tailored development paradigm,» says CIC Executive Committee member and a lead investigator in the ipilimumab clinical development program Jedd D. Wolchok, M.D., Ph.D., who is director of the Immunotherapy Clinical Trials Program at Memorial Sloan - Kettering Cancer Center in New York City.

Ipilimumab is the second active immunotherapy for cancer to be approved by the FDA, following the approval in April 2010 of sipuleucel - T (Provenge ®) for advanced castrate - resistant prostate cancer.

This anti-PD-1 antibody works in a complementary fashion to ipilimumab and can be combined with it for more powerful results, as has been recently shown by a clinical trial conducted by CRI Scientific Advisory Council associate director Jedd Wolchok.

The first drug of this kind was the anti-CTLA-4 antibody called ipilimumab, which is manufactured by Bristol - Myers Squibb and which the FDA approved in 2011.

Following the US Food and Drug Administration (FDA) approval of ipilimumab the following year, approvals of other targeted therapies (against BRAF and MEK), and most recently, approvals and extended indications for other checkpoint inhibitors, especially the programmed death 1 (PD - 1) / programmed death ligand 1 (PD - L1) inhibitors, have constituted a revolution characterized by higher response rates and the potential for extended survival.

By 2000, Korman and Lonberg had used this approach to create a human antibody, ipilimumab, that binds and inactivates CTLA - 4.

In the spring of 2011, the FDA approved the immunotherapy treatment ipilimumab, known by the brand name Yervoy.